Recent progress in discovery of novel AAK1 inhibitors: from pain therapy to potential anti-viral agents

References

• Wasner G. Central pain syndromes. Curr Pain Headache Rep. 2010;14(6):489–496.
   PubMed Web of Science ®Google Scholar
• Sorensen EB, Conner SD. AAK1 regulates Numb function at an early step in clathrin-mediated endocytosis. Traffic. 2008;9(10):1791–1800.
   PubMed Web of Science ®Google Scholar
• Sorrell FJ, Szklarz M, Abdul Azeez KR, Elkins JM, Knapp S. Family-wide structural analysis of human numb-associated protein kinases. Structure. 2016;24(3):401–411.
   PubMed Web of Science ®Google Scholar
• Smythe E, Ayscough KR. The Ark1/Prk1 family of protein kinases. Regulators of endocytosis and the actin skeleton. EMBO Rep. 2003;4(3):246–251.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Furuchi T, Naganuma A. Endocytic Ark/Prk kinases play a critical role in adriamycin resistance in both yeast and mammalian cells. Cancer Res. 2006;66(24):11932–11937.
   PubMed Web of Science ®Google Scholar
• Conner SD, Schröter T, Schmid SL. AAK1-mediated micro2 phosphorylation is stimulated by assembled clathrin. Traffic. 2003;4(12):885–890.
   PubMed Web of Science ®Google Scholar
• Conner SD, Schmid SL. Identification of an adaptor-associated kinase, AAK1, as a regulator of clathrin-mediated endocytosis. J Cell Biol. 2002;156(5):921–929.
   PubMed Web of Science ®Google Scholar
• Fu X, Ke M, Yu W, Wang X, Xiao Q, Gu M, Lü Y. Periodic variation of AAK1 in an Aβ1-42-induced mouse model of Alzheimer’s disease. J Mol Neurosci. 2018;65(2):179–189.
   PubMed Web of Science ®Google Scholar
• Latourelle JC, Pankratz N, Dumitriu A, Wilk JB, Goldwurm S, Pezzoli G, Mariani CB, DeStefano AL, Halter C, Gusella JF, et al. Genomewide association study for onset age in Parkinson disease. BMC Med Genet. 2009;10(1):98.
   PubMedGoogle Scholar
• Shi B, Conner SD, Liu J. Dysfunction of endocytic kinase AAK1 in ALS. Int J Mol Sci. 2014;15(12):22918–22932.
   PubMed Web of Science ®Google Scholar
• Luo G, Chen L, Kostich WA, Hamman B, Allen J, Easton A, Bourin C, Gulianello M, Lippy J, Nara S, et al. Discovery of (S)-1-((2',6-Bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine (BMS-986176/LX-9211): a highly selective, CNS penetrable, and orally active adaptor protein-2 associated kinase 1 inhibitor in clinical trials for the treatment of neuropathic pain. J Med Chem. 2022;65(6):4457–4480.
   PubMed Web of Science ®Google Scholar
• Gil C, Ginex T, Maestro I, Nozal V, Barrado-Gil L, Cuesta-Geijo MÁ, Urquiza J, Ramírez D, Alonso C, Campillo NE, et al. COVID-19: drug targets and potential treatments. J Med Chem. 2020;63(21):12359–12386.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, Richardson P. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–402.
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020;81(2):318–356.
   PubMed Web of Science ®Google Scholar
• Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Rawling M, Savory E, Stebbing J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–e31.
   PubMed Web of Science ®Google Scholar
• Neveu G, Barouch-Bentov R, Ziv-Av A, Gerber D, Jacob Y, Einav S. Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly. PLoS Pathog. 2012;8(8):e1002845.
   PubMed Web of Science ®Google Scholar
• Einav S, Rina B-B, Neveu G, et al. Methods and composition for treating viral diseases. 2013, US2013086133.
   Google Scholar
• Krahn AI, Wells C, Drewry DH, Beitel LK, Durcan TM, Axtman AD. Defining the neural kinome: strategies and opportunities for small molecule drug discovery to target neurodegenerative diseases. ACS Chem Neurosci. 2020;11(13):1871–1886.
   PubMed Web of Science ®Google Scholar
• Cossart P, Helenius A. Endocytosis of viruses and bacteria. Cold Spring Harb Perspect Biol. 2014;6(8):a016972–a016972.
   PubMed Web of Science ®Google Scholar
• Martinez-Gualda B, Schols D, De Jonghe S. A patent review of adaptor associated kinase 1 (AAK1) inhibitors (2013-present). Expert Opin Ther Pat. 2021;31(10):911–936. 36.
   PubMed Web of Science ®Google Scholar
• Xin X, Wang Y, Zhang L, Zhang D, Sha L, Zhu Z, Huang X, Mao W, Zhang J. Development and therapeutic potential of adaptor-associated kinase 1 inhibitorsin human multifaceted diseases. Eur J Med Chem. 2023;248:115102.
   PubMed Web of Science ®Google Scholar
• Cope MJ, Yang S, Shang C, Drubin DG. Novel protein kinases Ark1p and Prk1passociate with and regulate the cortical actin cytoskeleton in budding yeast. J Cell Biol. 1999; 144(6):1203–1218.
   PubMed Web of Science ®Google Scholar
• Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298(5600):1912–1934.
   PubMed Web of Science ®Google Scholar
• Henderson DM, Conner SD. A novel AAK1 splice variant functions at multiple steps of the endocytic pathway. Mol Biol Cell. 2007;18(7):2698–2706.
   PubMed Web of Science ®Google Scholar
• Ultanir SK, Hertz NT, Li G, Ge WP, Burlingame AL, Pleasure SJ, Shokat KM, Jan LY, Jan YN. Chemical genetic identification of NDR1/2 kinase substrates AAK1 and Rabin8 uncovers their roles in dendrite arborization and spine development. Neuron. 2012;73(6):1127–1142.
   PubMed Web of Science ®Google Scholar
• Golkowski M, Lius A, Sapre T, Lau HT, Moreno T, Maly DJ, Ong SE. Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity. Mol Cell. 2023;83(5):803–818.e8.
   PubMed Web of Science ®Google Scholar
• Borner GH, Antrobus R, Hirst J, Bhumbra GS, Kozik P, Jackson LP, Sahlender DA, Robinson MS. Multivariate proteomic profiling identifies novel accessory proteins of coated vesicles. J Cell Biol. 2012;197(1):141–160.
   PubMed Web of Science ®Google Scholar
• Krieger JR, Taylor P, Gajadhar AS, Guha A, Moran MF, McGlade CJ. Identification and selected reaction monitoring (SRM) quantification of endocytosis factors associated with Numb. Mol Cell Proteomics. 2013;12(2):499–514.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhang T, Zhang X, Jiang Z, Peng M, Huang Z. BMP2K dysregulation promotes abnormal megakaryopoiesis in acute megakaryoblastic leukemia. Cell Biosci. 2020;10(1):57.
   PubMed Web of Science ®Google Scholar
• Chaikuad A, Keates T, Vincke C, Kaufholz M, Zenn M, Zimmermann B, Gutiérrez C, Zhang RG, Hatzos-Skintges C, Joachimiak A, et al. Structure of cyclin G-associated kinase (GAK) trapped in different conformations using nanobodies. Biochem J. 2014;459(1):59–69.
   PubMedGoogle Scholar
• Tian X, Inoue K, Zhang Y, Wang Y, Sperati CJ, Pedigo CE, Zhao T, Yan M, Groener M, Moledina DG, et al. Inhibiting calpain 1 and 2 in cyclin G associated kinase-knockout mice mitigates podocyte injury. JCI Insight. 2020;5(22):e142740.
   PubMed Web of Science ®Google Scholar
• In JG, Striz AC, Bernad A, Tuma PL. Serine/threonine kinase 16 and MAL2 regulate constitutive secretion of soluble cargo in hepatic cells. Biochem J. 2014;463(2):201–213.
   PubMedGoogle Scholar
• Stairs DB, Notarfrancesco KL, Chodosh LA. The serine/threonine kinase, Krct, affects endbud morphogenesis during murine mammary gland development. Transgenic Res. 2005;14(6):919–940.
   PubMed Web of Science ®Google Scholar
• Kuai L, Ong SE, Madison JM, Wang X, Duvall JR, Lewis TA, Luce CJ, Conner SD, Pearlman DA, Wood JL, et al. AAK1 identified as an inhibitor of neuregulin-1/ErbB4-dependent neurotrophic factor signaling using integrative chemical genomics and proteomics. Chem Biol. 2011;18(7):891–906.
   PubMedGoogle Scholar
• Lian J, Zhu X, Du J, Huang B, Zhao F, Ma C, Guo R, Zhang Y, Ji L, Yahaya BH, et al. Extracellular vesicle-transmitted miR-671-5p alleviates lung inflammation and injury by regulating the AAK1/NF-κB axis. Mol Ther. 2023;31(5):1365–1382.
   PubMed Web of Science ®Google Scholar
• Abhinand CS, Galipon J, Mori M, Ramesh P, Prasad TSK, Raju R, Sudhakaran PR, Tomita M. Temporal phosphoproteomic analysis of VEGF-A signaling in HUVECs: an insight into early signaling events associated with angiogenesis. J Cell Commun Signal. 2023;17(3):1067–1079.
   PubMed Web of Science ®Google Scholar
• Abhinand CS, Raju R, Soumya SJ, Arya PS, Sudhakaran PR. VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis. J Cell Commun Signal. 2016;10(4):347–354.
   PubMed Web of Science ®Google Scholar
• Agajanian MJ, Walker MP, Axtman AD, Ruela-de-Sousa RR, Serafin DS, Rabinowitz AD, Graham DM, Ryan MB, Tamir T, Nakamichi Y, et al. WNT activates the AAK1 kinase to promote clathrin-mediated endocytosis of LRP6 and establish a negative feedback loop. Cell Rep. 2019;26(1):79.e8–93.e8.
   Web of Science ®Google Scholar
• MacGrogan D, Münch J, de la Pompa JL. Notch and interacting signalling pathways in cardiac development, disease, and regeneration. Nat Rev Cardiol. 2018;15(11):685–704.
   PubMed Web of Science ®Google Scholar
• Gupta-Rossi N, Ortica S, Meas-Yedid V, Heuss S, Moretti J, Olivo-Marin JC, Israël A. The adaptor-associated kinase 1, AAK1, is a positive regulator of the Notch pathway. J Biol Chem. 2011;286(21):18720–18730.
   PubMed Web of Science ®Google Scholar
• Nusse R, Clevers H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985–999.
   PubMed Web of Science ®Google Scholar
• Yang WK, Peng YH, Li H, Lin HC, Lin YC, Lai TT, Suo H, Wang CH, Lin WH, Ou CY, et al. Nak regulates localization of clathrin sites in higher-order dendrites to promote local dendrite growth. Neuron. 2011;72(2):285–299.
   PubMed Web of Science ®Google Scholar
• Shehata SN, Deak M, Collodet C, Spiegl SF, Geley S, Sumpton D, Sakamoto K. Identification of novel PCTAIRE-1/CDK16 substrates using a chemical genetic screen. Cell Signal. 2019;59:53–61.
   PubMed Web of Science ®Google Scholar
• Chen C, Chu CH, Chu Y, Chang TY, Chen SW, Liang SY, Tsai YC, Chen BC, Tu HL, Cheng PL. Neuronal paxillin and drebrin mediate BDNF-induced force transduction and growth cone turning in a soft-tissue-like environment. Cell Rep. 2022;40(7):111188.
   PubMed Web of Science ®Google Scholar
• Kostich W, Hamman BD, Li YW, Naidu S, Dandapani K, Feng J, Easton A, Bourin C, Baker K, Allen J, et al. Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain. J Pharmacol Exp Ther. 2016;358(3):371–386.
   PubMed Web of Science ®Google Scholar
• Louis JV, Lu Y, Pieschl R, Tian Y, Hong Y, Dandapani K, Naidu S, Vikramadithyan RK, Dzierba C, Sarvasiddhi SK, et al. [3H]BMT-046091 a potent and selective radioligand to determine AAK1 distribution and target engagement. Neuropharmacology. 2017;118:167–174.
   PubMed Web of Science ®Google Scholar
• Chen Y, Gao X, Pei H. miRNA-384-3p alleviates sevoflurane-induced nerve injury by inhibiting Aak1 kinase in neonatal rats. Brain Behav. 2022;12(7):e2556.
   PubMed Web of Science ®Google Scholar
• Huang C, Ji C, Wang J. Current thoughts on cellular functions of numb-associated kinases. Mol Biol Rep. 2023;50(5):4645–4652.
   PubMed Web of Science ®Google Scholar
• Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26(1):127–132.
   PubMed Web of Science ®Google Scholar
• Neveu G, Ziv-Av A, Barouch-Bentov R, Berkerman E, Mulholland J, Einav S. AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets. J Virol. 2015;89(8):4387–4404.
   PubMed Web of Science ®Google Scholar
• Bekerman E, Neveu G, Shulla A, Brannan J, Pu SY, Wang S, Xiao F, Barouch-Bentov R, Bakken RR, Mateo R, et al. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J Clin Invest. 2017;127(4):1338–1352.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Krishnan V, de Bono S, Ottaviani S, Casalini G, Richardson PJ, Monteil V, Lauschke VM, Mirazimi A, Youhanna S, et al. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med. 2020;12(8):e12697.
   PubMed Web of Science ®Google Scholar
• Akbarzadeh-Khiavi M, Torabi M, Rahbarnia L, Safary A. Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection. Infection. 2022;50(2):295–308.
   PubMed Web of Science ®Google Scholar
• Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, et al. Characterization of spikeglycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020; 11(1):1620.
   PubMed Web of Science ®Google Scholar
• Kar P, Saleh-E-In MM, Jaishee N, Anandraj A, Kormuth E, Vellingiri B, Angione C, Rahman PKSM, Pillay S, Sen A, et al. Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19. J Cell Biochem. 2022;123(5):964–986. 75.
   PubMed Web of Science ®Google Scholar
• Lo Caputo S, Corso G, Clerici M, Santantonio TA. Baricitinib: A chance to treat COVID-19? J Med Virol. 2020;92(11):2343–2344.
   PubMed Web of Science ®Google Scholar
• Moreno-González G, Mussetti A, Albasanz-Puig A, Salvador I, Sureda A, Gudiol C, Salazar R, Marin M, Garcia M, Navarro V, et al. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: a structured summary of a study protocol for a randomised controlled trial. Trials. 2021;22(1):116.
   PubMed Web of Science ®Google Scholar
• Lin Q, Li J, Wang Y, Zang J. Design, synthesis, and biological evaluation of novel ruxolitinib and baricitinib analogues for potential use against COVID-19. Chem Biol Drug Des. 2023;101(3):760–771.
   PubMed Web of Science ®Google Scholar
• Bi YZ, Carson KG, Cianchetta G, Green MA, Kumi G, Liang Z, Liu YJ, Main A, Zhang YL, Zipp CG. Imidazo[1,2-b]pyridazine-based compounds compositions comprisingthem, and uses thereof. 2013, WO2013134219A1
   Google Scholar
• Lanthorn TH, Savelieva K, Zambrowicz B. Inhibition of adaptor associated kinase 1 for the treatment of pain. 2013, WO2013134336A2.
   Google Scholar
• Hartz RA, Ahuja VT, Rajamani R, Dzierba CD, Bronson JJ, Macor JE. Imidazopyridazine kinase inhibitors useful for treating a disease or disorder mediated by AAK1, such as Alzheimer’s disease, bipolar disorder, pain, and schizophrenia, WO2015026574A1. 2015.
   Google Scholar
• Bi YZ, Carson KG, Cianchetta G, Green MA, Kumi G, Liang Z, Liu YJ, Main A, Zhang YL, Zipp CG. pyrazolo[1,5-a]pyrimidine-based compounds as adaptor associated kinase 1 inhibitors, compositions comprising them, and methods of their use, WO2013134228A1. 2013.
   Google Scholar
• Bi YZ, Kumi G. Inhibitors of adapter associated kinase 1, compositions comprising them, and methods of their use. 2015, WO2015142714A1.
   Google Scholar
• Bi YZ, Gardyan MW, Green MG, Kumi G, Zhang YL. Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of use. 2015, WO2015035117A1.
   Google Scholar
• Gopinathan S, Tyle P, Yang QM. 4-(3-(Pyridin-3-yl)pyrazolo[1,5-A]pyrimidin-5-yl)piperazine for use in the treatment of COV-229E OR COV-OC43 coronaviruses infections. 2021, WO2021216454A1.
   Google Scholar
• Hartz RA, Ahuja VT, Nara SJ, Kumar CMV, Brown JM, Bristow LJ, Rajamani R, Muckelbauer JK, Camac D, Kiefer SE, et al. Discovery, structure-activity relationships, and in vivo evaluation of novel aryl amides as brain penetrant adaptor protein 2-associated kinase 1 (AAK1) inhibitors for the treatment of neuropathic pain. J Med Chem. 2021;64(15):11090–11128.
   PubMed Web of Science ®Google Scholar
• Hartz RA, Ahuja VT, Nara SJ, Kumar CMV, Manepalli R, Sarvasiddhi SK, Honkhambe S, Patankar V, Dasgupta B, Rajamani R, et al. Bicyclic heterocyclic replacement of an aryl amide leading to potent and kinase-selective adaptor protein 2-associated kinase 1 inhibitors. J Med Chem. 2022;65(5):4121–4155.
   PubMed Web of Science ®Google Scholar
• Luo G, Chen L, Kostich WA, Hamman B, Allen J, Easton A, Bourin C, Gulianello M, Lippy J, Nara S, et al. Discovery and optimization of biaryl alkyl ethers as a novel class of highly selective, CNS-penetrable, and orally active adaptor protein-2-associated kinase 1 (AAK1) inhibitors for the potential treatment of neuropathic pain. J Med Chem. 2022;65(6):4534–4564.
   PubMed Web of Science ®Google Scholar
• Verdonck S, Pu SY, Sorrell FJ, Elkins JM, Froeyen M, Gao LJ, Prugar LI, Dorosky DE, Brannan JM, Barouch-Bentov R, et al. Synthesis and structure-activity relationships of 3,5-disubstituted-pyrrolo[2,3-b]pyridines as inhibitors of adaptor-associated kinase 1 with antiviral activity. J Med Chem. 2019;62(12):5810–5831.
   PubMed Web of Science ®Google Scholar
• Wells C, Couñago RM, Limas JC, Almeida TL, Cook JG, Drewry DH, Elkins JM, Gileadi O, Kapadia NR, Lorente-Macias A, et al. SGC-AAK1-1: a chemical probe targeting AAK1 and BMP2K. ACS Med Chem Lett. 2020;11(3):340–345.
   PubMed Web of Science ®Google Scholar